Biologic agents used in the treatment of psoriasis include the anti-TNF agents adalimumab, etanercept, and infliximab, the anti-interleukin (IL)-12/23 antibody ustekinumab, and the anti-IL-17 antibody secukinumab. In 2005, the US Food and Drug Administration (FDA) issued an alert about a possible link between topical tacrolimus and pimecrolimus and cases of lymphoma and skin cancer in children and adults 51, and in 2006 placed a black box warning on the prescribing information for these medications 52. Ustekinumab Ustekinumab is a human monoclonal antibody that targets IL-12 and IL-23. It is also used to treat plaque psoriasis, which is a chronic inflammatory skin disease. Biological medicines like etanercept are sometimes called cytokine modulators, or monoclonal antibodies. Ustekinumab is the most recent monoclonal antibody (biologic) approved in the U. Several new agents to treat psoriasis are under study, including oral medications and injectable agents. Because these drugs are also used to treat psoriasis, this rebound effect is of particular concern.
The etanercept group received subcutaneous injections of the drug twice weekly for 12-weeks while the ustekinumab group received 2 injections, one-month apart, of either 90 or 45 milligrams. In Phase III trials in patients with moderate to severe plaque psoriasis, significantly more subcutaneous ustekinumab 45 or 90 mg recipients (administered as two injections 4 weeks apart) than placebo recipients achieved a 75 improvement on the Psoriasis Area and Severity Index (PASI 75) score at 12 weeks. Clinical trials that have investigated the role of biologics in psoriasis therapy are reviewed in Table 2a and and2b2b. Subcutaneously injected adalimumab was found to have superior efficacy of achieving PASI 75 in comparison to placebo in several phase 2 and phase 3 trials. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial. Secukinumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in people whose psoriasis is too severe to be treated by topical medications alone. Secukinumab injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.
Ustekinumab (Stelera) is a monoclonal antibody (biologic) injection approved in the U. Because these drugs are also used to treat psoriasis, this rebound effect is of particular concern. Secukinumab (Cosentyx) is a newly approved recombinant human monoclonal antibody used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (or both). Phototherapy is a first line therapy for moderate to severe psoriasis. Efalizumab is a humanized monoclonal antibody directed against the CD-11a subunit of leukocyte function antigen-1 (LFA-1) expressed on T cells. For the treatment of severe plaque psoriasis and PsA (with or without MTX), infliximab is delivered by an intravenous infusion over a 2-hour period at weeks 0, 2, and 6 followed by maintenance infusions every 8 weeks. For patients weighing 100kg or less, 45mg is injected SQ initially, 4 weeks later, then every 12 weeks thereafter.
Efalizumab is a recombinant monoclonal antibody, prescribed for chronic, moderate to severe plaque psoriasis. It is an interleukin-12/23 human monoclonal antibody. Scales, Plaques & Eruptions. Humira is used for pain relief and to reduce inflammation in a number of autoimmune diseases. The word HUMIRA stands for HUman Monoclonal Antibody In Rheumatoid Arthritis. It can be injected with a syringe or a preloaded pen device (Humira Pen) subcutaneously, usually by the patient at home. Ustekinumab is a novel investigational human monoclonal antibody (mAb) that is pending approval for the treatment of plaque psoriasis. Subcutaneous administration of ustekinumab has demonstrated efficacy in both phase 2 and 3 trials. Although there is no cure for plaque psoriasis, treatment is directed at decreasing symptom severity and improving HRQOL. Pharmacologic Class: Monoclonal Antibody. Uses For Cosentyx. Secukinumab injection is used to treat moderate-to-severe plaque psoriasis in patients who may benefit from receiving phototherapy (ultraviolet light treatment) or other treatments. Treatment for psoriasis includes creams, ointments, injections, and phototherapy. Common drug classes used to treat psoriasis are antifolates, beta hydroxy acids, CNI immunosuppressants, psoralens, retinoids, TNF blockers, corticosteroid / vitamin D analogue combinations, vitamin D analogues, keratolytics, interleukin antagonists, antipsoriatics, and corticosteroid / keratolytic combinations. Taltz (ixekizumab) will offer another treatment option for plaque psoriasis. Monoclonal antibodies are used to treat many diseases, including cancer;
The clinical features of plaque psoriasis vary due to many factors, including chronicity of disease, size of the lesions, body sites, percentage of body surface area (BSA) involved, symptomatology, such as pruritus, burning, or pain, associated joint disease, and prior therapy. The commonest side effects were headache, chills, fever, nausea, vomiting, or myalgia occurring on the day of injection or in the following two days during the initial three weeks of therapy. Infliximab, a chimeric anti-TNF monoclonal antibody administered by intravenous infusion, was the first TNF blocker studied for the treatment of psoriasis.